Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.64 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124242 | 1.00 | P4HTM (0.64) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL28774613 | 0.87 | NFE2L2 (0.47) | P4HTMPKMRAB9AKDM4EMAPK1 | |
| SCHEMBL18693467 | 0.86 | P4HTM (0.47) | P4HTMRAB9ANAPRTHDAC3HDAC4 | |
| SCHEMBL18693464 | 0.86 | P4HTM (0.47) | P4HTMRAB9ANAPRTHDAC3HDAC4 | |
| SCHEMBL29612143 | 0.84 | NFE2L2 (0.45) | P4HTMRAB9AKDM4ENAPRTNFE2L2 | |
| SCHEMBL9180282 | 0.82 | MAOB (0.64) | PKMRAB9AHDAC3HDAC4HDAC1 | |
| SCHEMBL6853074 | 0.81 | P4HTM (0.68) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL8731557 | 0.81 | P4HTM (0.68) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL11660064 | 0.81 | P4HTM (0.68) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL29789035 | 0.81 | P4HTM (0.68) | P4HTMHCAR2CA12AKR1B10CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573502-B | Pleuromutilin aromatic heterocyclic acrylate compound, and synthetic method and application thereof | 西安康远晟生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-114573502-A | Pleuromutilin aromatic heterocyclic acrylate compounds and synthesis method and application thereof | 西安康远晟生物医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-9938258-B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| EP-2925750-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2054411-B1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORP (KR) | 2014-08-20 | — | — | EP | disclosed |
| WO-2014085607-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20110281869-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | AISSAOUI HAMED (FR) | 2011-11-17 | — | — | US | disclosed |
| EP-2282996-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-7858621-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2010-12-28 | — | — | US | disclosed |
| WO-2008013414-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-01-31 | — | — | WO | disclosed |
| EP-1882687-A1 | Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same | Amorepacific Corporation (KR) | 2008-01-30 | — | — | EP | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
| US-5039684-A | Absorption when administered orally | VALEAS S. P. A. (IT) | 1991-08-13 | — | — | US | disclosed |
| EP-0210782-B1 | PYRIDINE COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1991-04-17 | — | — | EP | disclosed |
| EP-0384450-A1 | Tetrazole amide derivatives of heterocyclic alkenyl acids and their use as antiallergic substances | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1990-08-29 | — | — | EP | disclosed |
| US-4778796-A | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| EP-0210782-A2 | Pyridine compounds, process for the preparation thereof and pharmaceutical composition containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | P4HTM 3332/4885HCAR2 102/4885CA12 3409/4885 |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | BCL6, MALT1, BCL3 | P4HTM 499/4885HCAR2 3625/4885CA12 918/4885 |
| US-20110281869-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | QTRT2, RECQL, QTRT1 | P4HTM 1934/4885HCAR2 2378/4885CA12 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.